Brise Pharma is a clinical-stage biopharmaceutical company focused on developing innovative treatment solutions for severe pain conditions, including migraine, inflammatory pain, and neuropathic pain. Established in June 2021 in Shanghai, China, the company leverages the extensive experience of its founding team, which has an average of over 15 years in drug research and development. Brise Pharma aims to provide safe, effective, and accessible pain management therapies through a well-balanced research and development pipeline that incorporates clinically validated targets and diverse therapeutic modalities. Their approach emphasizes collaboration with key opinion leaders in the field to enhance research efficiency and therapeutic outcomes.

The company is committed to innovation in pain management, utilizing a combination of original innovations and optimal technologies to address the needs of patients suffering from debilitating pain conditions. Brise Pharma's strategy includes building a balanced pipeline that not only focuses on internal research but also seeks external collaborations to expand its therapeutic offerings. By fostering a robust network and maintaining a strong focus on research excellence, Brise Pharma aspires to become a global leader in the treatment of pain diseases, ultimately improving the quality of life for patients both in China and worldwide.

China

Brise Pharma is a clinical stage biopharmaceutical company with a major focus on the development of innovative and highly differentiated treatments for chronic pain.

Brise Pharma

Company Details